Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
|Articles|May 2, 2019
- Pharmaceutical Technology-05-02-2019
- Volume 43
- Issue 5
New Pneumatic Presses
Wabash MPI and Carver’s PNP Series is a new line of pneumatic presses for a variety of applications, including composites molding, laminating, rubber molding, plastics testing, fluid/resin extraction, destructive testing, bonding, cell disruption, and sample preparation.
Wabash MPI and Carver’s PNP Series is a new line of pneumatic presses for a variety of applications, including composites molding, laminating, rubber molding, plastics testing, fluid/resin extraction, destructive testing, bonding, cell disruption, and sample preparation. Standard models in .5-, 2-, and 5-ton capacities and feature table-top, four-post construction. Maximum operating temperature is 500 ºF. Other standard features include low-friction seals and bearings, infinite-life framework, interchangeable cylinders along with 90-psig design pressure and five-micron particulate air filters. Optional features range from CE and cleanroom designs to platen cooling, heat tubes, 800 ºF operation, and more.
Articles in this issue
over 7 years ago
Closed Systems for Aseptic Fill and Finishover 7 years ago
Contract Packaging Growsover 7 years ago
New Kit Identifies Endonuclease Impuritiesover 7 years ago
New Size for AODD Pumpover 7 years ago
1000-Gallon Pivoting Triple Shaft Mixerover 7 years ago
Bioprocessing Facilities and FDA Inspection Problemsover 7 years ago
FDA Faces Challenges After Gottliebover 7 years ago
The Auditor Vs. Inspector Issueover 7 years ago
Avoiding Excipient Variabilityover 7 years ago
Working for the Greater GoodRelated to this article
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.